A carregar...
Publicação
BioXtereo: a company making histology ready for the future-financial framework of BioXtereo: analysis, valuation, and future financial strategies
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 17.17 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
BioXtereo, a spin-off resulting from a collaboration with scientists from Instituto Gulbenkian de Ciência (IGC), addresses the scarcity of histology specialists in preclinical studies, which is critical for medical advancements. In a world approaching 10 billion people in 2030, ensuring ‘Good Health and Wellbeing’ is vital. The labor shortage of histologists poses a significant challenge. BioXtereo’s innovative solution, InSitulign, precisely aligns tissue samples, reducing errors and costs in research. BioXtereo envisions itself becoming a prominentleader in the biotech industry, actively shaping its future, and contributing to the pursuit of a healthier world.
Descrição
Palavras-chave
Science-based entrepreneurship Venture capital Innovation Histology Additive manufacturing Entrepreneurial finance Research and development